QNRX

← Markets

QNRXQuoin Pharmaceuticals, Ltd.

Discussion

Nothing said here yet.

to join the conversation.

—

Fri, Aug 28
7:48 AMSeeking AlphaQuoin Pharmaceuticals secures up to $50M financing to fund rare disease pipeline; shares rally
5:00 AMglobenewswire.comQuoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
5:00 AMglobenewswire.comQuoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Thu, Aug 27
10:25 AMYahooQNRX: Believe Conditional FDA Approval of Proposed Brand Name Reflects QRX003 Nearing Potential Commercialization
Fri, Aug 14
7:30 AMYahooQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Fri, Aug 7
7:30 AMYahooQuoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
Thu, Jul 9
7:30 AMYahooQuoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Tue, Jun 30
7:30 AMYahooQuoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
Tue, Jun 23
7:30 AMYahooQuoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
Thu, Jun 18
7:30 AMYahooQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Tue, Jun 16
7:30 AMYahooQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Thu, Jun 4
7:30 AMYahooQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome